Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 01, 2009 (Vol. 29, No. 19)

Therapeutic Targets Database

  • Easy-to-use, links directly to primary literature
  • None

The ultimate goal of biomedical research is to apply newfound knowledge of the human body and disease toward the development of novel therapies. The Bioinformatics and Drug Design Group at the National University of Singapore offers a wonderful online access point to the world of drug design, the Therapeutic Targets Database (TTD). The TTD is the type of database one loves to explore. It doesn’t matter if you’re searching for a drug, a disease, a target protein, or a metabolic pathway—just type your query into the search field. It’s as simple as that. The TTD excels in combining these various search parameters as well as in linking scientists directly to the literature. Once the search results are displayed and the target of interest selected, a great deal of information is provided, including literature references. These references are linked to PubMed, so inquirers can directly access the primary literature from the TTD’s website.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »